DK0593516T3 - Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien - Google Patents

Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien

Info

Publication number
DK0593516T3
DK0593516T3 DK92912453T DK92912453T DK0593516T3 DK 0593516 T3 DK0593516 T3 DK 0593516T3 DK 92912453 T DK92912453 T DK 92912453T DK 92912453 T DK92912453 T DK 92912453T DK 0593516 T3 DK0593516 T3 DK 0593516T3
Authority
DK
Denmark
Prior art keywords
bdnf
motor neuron
members
methods
neuron diseases
Prior art date
Application number
DK92912453T
Other languages
Danish (da)
English (en)
Inventor
Vivien Wong
Czeslaw Radziejewski
Peter Distefano
Original Assignee
Regeneron Pharma
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Max Planck Gesellschaft filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK0593516T3 publication Critical patent/DK0593516T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Water Treatments (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Water Treatment By Sorption (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK92912453T 1991-07-10 1992-05-19 Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien DK0593516T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72770491A 1991-07-10 1991-07-10
PCT/US1992/004228 WO1993001300A1 (fr) 1991-07-10 1992-05-19 Methodes de traitement de maladies des neurones moteurs utilisant des elements de la famille des molecules bdnf/nt-3/ngf

Publications (1)

Publication Number Publication Date
DK0593516T3 true DK0593516T3 (da) 2001-09-17

Family

ID=24923677

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92912453T DK0593516T3 (da) 1991-07-10 1992-05-19 Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien

Country Status (20)

Country Link
EP (2) EP0593516B1 (fr)
JP (1) JPH06509094A (fr)
CN (1) CN1065768C (fr)
AT (1) ATE202939T1 (fr)
AU (2) AU675409B2 (fr)
CA (1) CA2113083A1 (fr)
DE (1) DE69231930T2 (fr)
DK (1) DK0593516T3 (fr)
ES (1) ES2157903T3 (fr)
FI (1) FI940098A7 (fr)
GR (1) GR3036776T3 (fr)
HU (1) HUT70275A (fr)
IE (1) IE921602A1 (fr)
IL (1) IL101928A0 (fr)
NO (1) NO940084L (fr)
PT (1) PT100501A (fr)
RU (1) RU94016525A (fr)
SK (1) SK2694A3 (fr)
WO (1) WO1993001300A1 (fr)
ZA (1) ZA923639B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025684A1 (fr) * 1992-06-12 1993-12-23 Regeneron Pharmaceuticals, Inc. Procedes therapeutique et diagnostique bases sur l'expression de la neurotrophine-4
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
AU2001259453B2 (en) 2000-05-05 2006-08-31 Beth Israel Deaconess Medical Center Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
WO2008156418A1 (fr) * 2007-06-19 2008-12-24 Astrazeneca Ab Procédé de criblage ou de diagnostic du syndrome de post-poliomyélite et de la fibromyalgie
MX2010001395A (es) * 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
WO2014111525A2 (fr) 2013-01-18 2014-07-24 Anaxomics Biotech, Sl Nouvelles polythérapies pour le traitement de maladies du système nerveux
WO2016210325A1 (fr) 2015-06-26 2016-12-29 C.R. Bard, Inc. Interface de raccord pour système de positionnement de cathéter basé sur ecg
WO2023164311A2 (fr) * 2022-02-28 2023-08-31 Bioincept, Llc Compositions et méthodes de traitement de la sclérose latérale amyotrophique (sla) et de troubles associés
GB202303495D0 (en) * 2023-03-09 2023-04-26 Ucl Business Ltd Therapy for charcot-marie-tooth disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
HU9400063D0 (en) 1994-06-28
IE921602A1 (en) 1993-01-13
PT100501A (pt) 1993-09-30
AU2009592A (en) 1993-02-11
ATE202939T1 (de) 2001-07-15
GR3036776T3 (en) 2002-01-31
RU94016525A (ru) 1996-06-10
EP0593516A4 (fr) 1995-01-18
NO940084D0 (no) 1994-01-10
JPH06509094A (ja) 1994-10-13
AU7067696A (en) 1997-01-16
SK2694A3 (en) 1995-02-08
DE69231930T2 (de) 2002-04-11
AU675409B2 (en) 1997-02-06
ZA923639B (en) 1993-02-24
FI940098A7 (fi) 1994-03-10
CA2113083A1 (fr) 1993-01-21
WO1993001300A1 (fr) 1993-01-21
EP0755682A1 (fr) 1997-01-29
EP0593516A1 (fr) 1994-04-27
NO940084L (no) 1994-03-08
HUT70275A (en) 1995-09-28
IL101928A0 (en) 1992-12-30
EP0593516B1 (fr) 2001-07-11
DE69231930D1 (de) 2001-08-16
CN1065768C (zh) 2001-05-16
CN1071585A (zh) 1993-05-05
ES2157903T3 (es) 2001-09-01
FI940098A0 (fi) 1994-01-10

Similar Documents

Publication Publication Date Title
FI108146B (fi) Biologisesti aktiivisten, neurotrofisten NGF/BDNF-sarjan yhdistelmäproteiinien valmistus
DK0593516T3 (da) Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
DE69634301D1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
DK0927024T3 (da) Indretning og fremgangsmåde til behandling af öjensygdomme
ATE545429T1 (de) Modulation der neurotrophinaktivität;screeningsverfahren
DE68919236D1 (de) Textilbehandlungszubereitung und deren Herstellung.
DE69203254D1 (de) Herstellung von Crackkatalysatoren und Crackverfahren mit diesen.
DK0517820T3 (da) Anvendelse af 3-guanidinopropionsyre ved fremstillingen af et lægemiddel til behandling og hindring af overdreven fedme
ATE199167T1 (de) Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
NO882853L (no) Korreksjon med dobbeltraadet rna av unormale tilstander i immunkomplekser som er i omloep, og i monocyttfunkjon.
DE3782346D1 (de) Verwendung von chinolon und naphthyridin-antibiotika zur herstellung von ophthalmischen arzneimitteln.
DE3770465D1 (de) Verwendung von zinn-protoporphyrin und zinn-mesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.
DK36889D0 (da) Anvendelse af et benzamidderivat til fremstilling af et middel til behandling eller forebyggelse af kognitive lidelser
ATA118995A (de) Humanes virussicheres monomeres immunglobulin a und verfahren zu seiner herstellung
AU7426487A (en) Method of treating depression using d-fenfluramine
FI891475A0 (fi) Foerfarande foer framstaellning av natriumfluoralkoholat.
RU93050675A (ru) Способ коррекции психофизиологического состояния человека
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
Aurela A systematic storytelling therapy.
DK0868914T3 (da) Farmaceutisk præparat til bekæmpelse og behandling af ano-rektal- og colon-sygdomme
RU97104417A (ru) Способ лечения заболеваний носа и устройство для его осуществления
DE19739761A1 (de) Verwendung von Ozon und zusätzlich noch dosierte Vitamin E Indikation zur Blutbehandlung
RU96117545A (ru) Способ лечения диабетической ретинопатии